The potential impact of RCC molecular subtypes on treatment outcomes
| Channel | Publish Date | Thumbnail & View Count | Download Video |
|---|---|---|---|
 | Publish Date not found |  0 Views |
Moderator: Jody Takemoto, Ph.D.
Guest: David Braun, MD, PhD
A recent study investigated whether molecular subtypes of renal cell carcinoma (RCC) impact treatment outcomes. Dr. David Braun, assistant professor of medicine and member of the Center for Molecular and Cellular Oncology at Yale Cancer Center, shares these surprising findings and their implications.
Please feel free to connect and share this video with your friends and family if you find it useful.
